Clinical trials: Cancer of the Esophagus
Breast Cancer, Metastatic Gastric Cancer
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the…
- Conditions
- Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
- Trial name
- NCT05183126
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gene Mutation-Related Cancer, Esophageal Cancer
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. However, about half patients received radiotherapy occurred relapse. Once relapse occurred, there is no better treatment strategy.
- Conditions
- Gene Mutation-Related Cancer, Esophageal Cancer, Radiation Exposure
- Trial name
- NCT04694391
- Testing
- whole exome sequence
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Esophageal Cancer
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
There are no standard chemotherapy regimens for metastatic esophageal cancer. Cisplatin plus 5-fluorouracil is widely used as first-line treatment with a response rate ranged from 30% to 40%.
- Trial name
- NCT01998347
- Testing
- Paclitaxel liposome, Cisplatin, 5-fluorouracil
- Where
- China
- Sponsor
- Shantou University Medical College
Colorectal Cancer, Esophageal Cancer
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00899626
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Vanderbilt University Medical Center
Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
- Trial name
- NCT00165490
- Testing
- Cetuximab, Cisplatin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Squamous Cell Carcinoma
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
This is a phase 2 trial investigating the effect and safety of pembrolizumab and photodynamic therapy (PDT) in metastatic esophageal squamous cell carcinoma failed at least one line of systemic treatment.
- Trial name
- NCT05386056
- Testing
- Pembrolizumab, Sinoporphyrin Sodium, Photodynamic therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University
Breast Cancer, Esophageal Cancer
Brodalumab in the Treatment of Immune-Related Adverse Events
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy.
- Conditions
- Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT06673329
- Testing
- Brodalumab, CT scan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brian Henick, MD
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Esophageal Cancer, Surgery
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown.
- Conditions
- Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
- Trial name
- NCT04280822
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
This is an open-label phase I study to evaluate the safety, tolerability, and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.
- Trial name
- NCT05427396
- Testing
- JS004, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Esophageal Cancer, Stomach Cancer
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
The survival of esophageal cancer and stomach cancer (EGC) at 5 years is less than 30%. Pravastatin is a potent inhibitor of HMG-CoA reductase inhibitor that has shown increased survival in patients with advanced hepatocellular…
- Trial name
- AGIM-1 (NCT01038154)
- Testing
- Pravastatin
- Where
- Spain
- Volunteers
- 146 people
- Sponsor
- Hospital Donostia
Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis
Clinical Study on the Effect of Removal of Porphyromonas Gingivalis on Prognosis of Esophageal Cancer After Radical Surgery
Esophagectomy is an important means of radical treatment of esophageal cancer, but due to local recurrence and metastasis, the 5-year survival rate of patients with esophageal cancer is only 20-30%.
- Trial name
- NCT06418945
- Testing
- Tinidazole oral microneedle patch
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma
Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.
- Trial name
- Poetry-1 (NCT02976896)
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Yuhong Li
Esophageal Cancer
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving cisplatin and irinotecan hydrochloride together with radiation therapy works in treating patients with esophageal cancer or gastroesophageal junction cancer that can be removed by…
- Trial name
- NCT00316862
- Testing
- cisplatin, irinotecan hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year.
- Trial name
- NCT05659251
- Testing
- Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, sample
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Neoplasms
PET-CT Based Radiotherapy in Esophageal Cancer Patients
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.
- Trial name
- NCT01156831
- Where
- 5 sites in Netherlands
- Volunteers
- 115 people
- Sponsor
- Maastricht Radiation Oncology
GERD, Barretts Esophagus
In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter
The purpose of this study is: To study the components of the gastroesophageal junction high-pressure zone individually and as a group, by pharmacologically eliminating or accentuating the pressure profile generated by the smooth…
- Trial name
- NCT00737802
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Malignant Solid Tumour, Gastroesophageal Cancer
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
This study is a Phase I/II trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors. In Phase I the Maximum Tolerated Dose (MTD) will be determined; in Phase II patients with first-line metastatic…
- Trial name
- NCT01611857
- Testing
- Tivantinib, FOLFOX
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- SCRI Development Innovations, LLC
Adenocarcinoma, Esophageal Cancer
Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma
There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas.
- Trial name
- SRCC (NCT01824966)
- Where
- Belgium
- Volunteers
- 82 people
- Sponsor
- University Hospital, Gasthuisberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.